CN104561095B - 一种能够生产人神经生长因子的转基因小鼠的制备方法 - Google Patents
一种能够生产人神经生长因子的转基因小鼠的制备方法 Download PDFInfo
- Publication number
- CN104561095B CN104561095B CN201510039597.5A CN201510039597A CN104561095B CN 104561095 B CN104561095 B CN 104561095B CN 201510039597 A CN201510039597 A CN 201510039597A CN 104561095 B CN104561095 B CN 104561095B
- Authority
- CN
- China
- Prior art keywords
- mouse
- gene
- ngf
- people
- homologous recombination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000699660 Mus musculus Species 0.000 title claims abstract description 22
- 238000011830 transgenic mouse model Methods 0.000 title claims abstract description 22
- 210000005036 nerve Anatomy 0.000 title claims description 11
- 239000003102 growth factor Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 93
- 238000002744 homologous recombination Methods 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 35
- 101150064037 NGF gene Proteins 0.000 claims abstract description 32
- 230000006801 homologous recombination Effects 0.000 claims abstract description 29
- 101100404651 Mus musculus Ngf gene Proteins 0.000 claims abstract description 28
- 241000699670 Mus sp. Species 0.000 claims abstract description 27
- 108020004414 DNA Proteins 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 14
- 210000000349 chromosome Anatomy 0.000 claims abstract description 6
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 6
- 210000003079 salivary gland Anatomy 0.000 claims abstract description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 4
- 210000000130 stem cell Anatomy 0.000 claims abstract description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 65
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 64
- 229940053128 nerve growth factor Drugs 0.000 claims description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 24
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 229950010131 puromycin Drugs 0.000 claims description 12
- 108020005004 Guide RNA Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000000520 microinjection Methods 0.000 claims description 9
- 230000033228 biological regulation Effects 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 210000002459 blastocyst Anatomy 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims description 3
- 238000001638 lipofection Methods 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 abstract description 23
- 238000003198 gene knock in Methods 0.000 abstract description 14
- 238000005516 engineering process Methods 0.000 abstract description 9
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 6
- 238000010363 gene targeting Methods 0.000 abstract description 4
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 3
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 210000001913 submandibular gland Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 230000007023 DNA restriction-modification system Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000004042 decolorization Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 102000046917 human NGF Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000011091 sodium acetates Nutrition 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012475 sodium chloride buffer Substances 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 101150033839 4 gene Proteins 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000989934 Mus musculus Hemoglobin subunit alpha Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 241000320123 Streptococcus pyogenes M1 GAS Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010053584 alpha-Globins Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000030363 nerve development Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510039597.5A CN104561095B (zh) | 2015-01-27 | 2015-01-27 | 一种能够生产人神经生长因子的转基因小鼠的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510039597.5A CN104561095B (zh) | 2015-01-27 | 2015-01-27 | 一种能够生产人神经生长因子的转基因小鼠的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104561095A CN104561095A (zh) | 2015-04-29 |
CN104561095B true CN104561095B (zh) | 2017-08-22 |
Family
ID=53078173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510039597.5A Active CN104561095B (zh) | 2015-01-27 | 2015-01-27 | 一种能够生产人神经生长因子的转基因小鼠的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104561095B (zh) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
CN105112449B (zh) * | 2015-09-02 | 2018-02-06 | 中国农业大学 | Cd28基因过表达载体及其应用 |
US20190225955A1 (en) | 2015-10-23 | 2019-07-25 | President And Fellows Of Harvard College | Evolved cas9 proteins for gene editing |
CN105671079A (zh) * | 2016-02-26 | 2016-06-15 | 华南农业大学 | 一种转人神经生长因子基因的小鼠及其制备方法和应用 |
DK3476865T3 (da) * | 2016-06-28 | 2023-12-18 | Biocytogen Pharmaceuticals Beijing Co Ltd | Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf |
KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN107815466B (zh) * | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
WO2018041118A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-l1 |
CN107815465B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
CN107815468B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
WO2018041119A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ox40 |
CN107955817B (zh) * | 2016-10-14 | 2020-02-28 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
CN108070614B (zh) * | 2016-11-11 | 2020-03-13 | 北京百奥赛图基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
CN108070613B (zh) | 2016-11-11 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
WO2018086594A1 (en) | 2016-11-11 | 2018-05-17 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tim-3 |
CN108239659B (zh) | 2016-12-23 | 2020-03-03 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
CN108424928B (zh) | 2016-12-30 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
CN108531487B (zh) * | 2017-03-31 | 2020-03-13 | 北京百奥赛图基因生物技术有限公司 | 人源化sirpa基因改造动物模型的制备方法及应用 |
CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
WO2019072241A1 (en) | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CN108342391A (zh) * | 2018-03-26 | 2018-07-31 | 江苏中新医药有限公司 | 提高rhNGF表达水平的内含子 |
CN109182340B (zh) * | 2018-09-28 | 2021-02-05 | 江苏集萃药康生物科技股份有限公司 | 一种ox40基因修饰人源化动物模型的构建方法和应用 |
CN109517840B (zh) * | 2018-11-06 | 2021-01-01 | 清华大学 | 果蝇生殖系统中高效的转录激活系统 |
CN111304247B (zh) | 2018-12-20 | 2021-03-16 | 百奥赛图江苏基因生物技术有限公司 | 人源化lag-3基因改造动物模型的制备方法及应用 |
CA3130488A1 (en) | 2019-03-19 | 2020-09-24 | David R. Liu | Methods and compositions for editing nucleotide sequences |
GB2614813A (en) | 2020-05-08 | 2023-07-19 | Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1686567A (zh) * | 2005-03-24 | 2005-10-26 | 中国医学科学院实验动物研究所 | 转人老年性痴呆症app基因的c57bl/6小鼠动物模型的建立和用途 |
CN101260398B (zh) * | 2007-03-07 | 2013-06-05 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子基因定位改造动物及其制备方法和应用 |
-
2015
- 2015-01-27 CN CN201510039597.5A patent/CN104561095B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104561095A (zh) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104561095B (zh) | 一种能够生产人神经生长因子的转基因小鼠的制备方法 | |
AU2016101604B4 (en) | Fertile transgenic animals useful for producing antibodies bearing human variable regions | |
Meade et al. | Bovine alphas1-casein gene sequences direct high level expression of active human urokinase in mouse milk | |
CN111733183B (zh) | 用于构建肝损伤小鼠模型的打靶载体、核酸组合物和构建方法 | |
US20030074681A1 (en) | Vectors and methods for tissue specific synthesis of protein in eggs of transgenic hens | |
CA2181433A1 (en) | Materials and methods for management of hyperacute rejection in human xenotransplantation | |
EA013564B1 (ru) | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция | |
CN104862318A (zh) | 利用转基因动物乳腺生物反应器生产单克隆抗体的方法 | |
AU2001259465B2 (en) | Transgenically produced decorin | |
CN101802210A (zh) | 在奶中产生外源蛋白的转基因哺乳动物 | |
CN113897369A (zh) | KRT10定点基因敲入P2A-CrePR1-T2A-tdTomato小鼠模型的构建及应用 | |
AU2001259465A1 (en) | Transgenically produced decorin | |
CN106978416B (zh) | 一种基因定位整合表达系统及其应用 | |
US7053262B2 (en) | Mammary gland tissue-specific expression system using β-casein promoter site of Korean native goat | |
KR100268713B1 (ko) | T-세포가 결핍된 유전자 이식 마우스 | |
DE60314017T2 (de) | Chimaeres protein enthaltend die cystein protease aus dem grossen leberegel fusioniert an das hepatitis b core protein oder ubiquitin; pflanzen, welches dieses protein exprimieren, sowie deren verwendung als vakzine | |
CN111019972A (zh) | 一种cd27人源化小鼠模型的构建方法及其应用 | |
KR100222916B1 (ko) | 한국산 재래종 산양의 베타카제인 프로모터를 이용한 유선조직 특이적 발현시스템 | |
US20240032515A1 (en) | Method for producing bird producing human immunoglobulin fc and target protein | |
CN107216379A (zh) | 半滑舌鳎igf‑i蛋白及其体外表达制备方法与应用 | |
CN100371441C (zh) | 用于在转基因雌禽卵中组织特异性合成蛋白质的载体与方法 | |
DK2649184T3 (en) | USE OF FERTILIZED TRANSGENE ANIMALS FOR THE MANUFACTURE OF ANTIBODIES CARRYING HUMAN VARIABLE REGIONS | |
CN109090040A (zh) | 一种制备Wnt10aflox/flox小鼠的方法及应用 | |
KR20010018852A (ko) | 인체 성장 호르몬 생산을 위한 형질 전환용 플라스미드pGbc5.5hGH(KCTC 8949P) | |
MXPA06000786A (en) | Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170601 Address after: Nanshan District Guangdong streets Shenzhen city in Guangdong province 518057 Ke Feng Lu No. 2 idiopathic information building, the first floor of building D No. two East Applicant after: SHENZHEN GUOCHUANG NANO ANTIBODY TECHNOLOGY CO.,LTD. Address before: High tech Zone of Jilin province Changchun 130303 Kumho Road No. 1357 building 708 Room Seven Applicant before: CHANGCHUN LITE BIOTECHNIQUE Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240119 Address after: 130103 708, 7th floor, no.1357 Jinhu Road, high tech Zone, Changchun City, Jilin Province Patentee after: CHANGCHUN LITE BIOTECHNIQUE Co.,Ltd. Address before: 518057 No.2, east side, 1st floor, building D, tefa infoport building, No.2 Kefeng Road, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province Patentee before: SHENZHEN GUOCHUANG NANO ANTIBODY TECHNOLOGY CO.,LTD. |